Latest Regulatory Clearance News

Page 1 of 38
Resonance Health delivered a $1.5 million profit and positive operating cash flow in every quarter of FY26, while raising $6 million to accelerate three growth programmes. The challenge is replacing a MASH trial that generated 48% of last year’s revenue.
Ada Torres
Ada Torres
19 Nov 2026
Sunrise Energy Metals has received unconditional FIRB approval for its proposed move to the United States, removing a key condition for the scheme. The company is targeting shareholder and Court approvals in January, with Nasdaq and ASX CDI trading expected to begin in February 2027.
Maxwell Dee
Maxwell Dee
19 Nov 2026
CurveBeam AI has received its first Chinese order for four HiRise weight-bearing CT systems from Weiying/Wego Orthopedics, turning regulatory clearance into an initial commercial foothold. The order value and delivery schedule were not disclosed, while a further A$1 million milestone investment is expected this quarter.
Victor Sage
Victor Sage
19 Nov 2026
Textron is selling its Industrial segment to Kingswood Capital Management for US$1.2 billion, reshaping the group around aviation, rotorcraft and defence. The deal could return about US$1.1 billion in net proceeds, but it also brings a sizeable non-cash impairment before closing.
Victor Sage
Victor Sage
18 Nov 2026
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Nuix has given Haveli five weeks of exclusive access to pursue a potential A$2.75-per-share cash takeover, valuing certainty at a substantial premium to the market price. The proposal is still non-binding, but the board intends to recommend it if Haveli delivers a binding offer on at least those terms.
Sophie Babbage
Sophie Babbage
18 Nov 2026
Auric Mining can now proceed with its proposed share purchase plan at A$0.185 per share, matching the price offered to placement investors despite sitting 21.5% below the relevant five-day VWAP. The waiver also allows directors and related parties to participate, subject to equal-treatment safeguards.
Maxwell Dee
Maxwell Dee
18 Nov 2026
PDI Gold has received Guinea’s final key exploitation permits for its Bankan development and Mansounia deposit, clearing the stated regulatory path to construction and mining. Bankan’s first gold remains targeted for mid-2028, while the company plans to release an updated schedule and capital estimate in early 2027.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Black Rock Mining has reshaped the funding plan for its Mahenge graphite project with a revised US$40 million POSCO subscription and a proposed US$70 million investment from African Critical Minerals. The package could cover most of Module 1, but it remains conditional on another US$40 million of equity, approvals and a lender deadline extension.
Maxwell Dee
Maxwell Dee
16 Nov 2026
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026

Browse the archive

Full archive